8-K: Alumis Envudeucitinib Shines in Phase 3 Psoriasis Trials

Alumis Inc. announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials for envudeucitinib, demonstrating leading skin clearance and a favorable safety profile in moderate-to-severe plaque psoriasis.

Summary

• Envudeucitinib met all primary and secondary endpoints with high statistical significance in Phase 3 ONWARD1 and ONWARD2 trials for moderate-to-severe plaque psoriasis.
• At Week 16, 74% of patients achieved Psoriasis Area and Severity Index (PASI) 75 and 59% achieved static Physicians Global Assessment (sPGA) 0/1 (co-primary endpoints) compared to placebo (p < 0.0001).
• At Week 24, approximately 65% of patients achieved PASI 90, and more than 40% achieved PASI 100, on average across both trials.
• Rapid onset of action was observed, with clear separation from placebo on PASI 90 as early as Week 4.
• Envudeucitinib demonstrated superior skin clearance compared to apremilast (p<0.0001) on all PASI endpoints at Week 24.
• The safety and tolerability profile was favorable and consistent with the Phase 2 program, including the long-term extension trial, with no new safety signals observed.
• The most common treatment-emergent adverse events (TEAEs) were headaches, nasopharyngitis, upper respiratory tract infections, and acne, with the majority being mild to moderate, transient, and responding to standard therapy.
• Alumis plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026.
• Topline data from the LUMUS Phase 2b trial of envudeucitinib in systemic lupus erythematosus (SLE) are expected to be announced in the third quarter of 2026.

Sentiment

Score: 9

Explanation: The filing reports highly positive Phase 3 clinical trial results for envudeucitinib, meeting all primary and secondary endpoints with high statistical significance, demonstrating leading efficacy and a favorable safety profile. This positions the drug as a potential best-in-class oral therapy for psoriasis and supports its broader pipeline potential, leading to a planned NDA submission.

Positives

• Envudeucitinib met all primary and secondary endpoints with high statistical significance in Phase 3 ONWARD1 and ONWARD2 trials.
• Achieved superior skin clearance compared to placebo (74% PASI 75 and 59% sPGA 0/1 at Week 16) and apremilast (p<0.0001 on all PASI endpoints at Week 24).
• Demonstrated deep skin clearance with approximately 65% achieving PASI 90 and over 40% achieving PASI 100 at Week 24, ranking among the strongest reported for an oral therapy.
• Showed rapid onset of action, with clear separation from placebo on PASI 90 as early as Week 4.
• Exhibited a favorable safety and tolerability profile consistent with the Phase 2 program, with no new safety signals observed.
• Observed consistent and clinically meaningful improvements across patient-reported outcomes relating to itch and quality of life.
• Positioned as a potential 'best-in-disease oral' for psoriasis and a 'pipeline-in-a-pill' for other immune-mediated diseases due to its highly differentiated clinical profile.

Risks

• Regulatory authorities may not determine that envudeucitinib in moderate-to-severe plaque psoriasis is sufficiently safe and efficacious and may not grant regulatory approval.
• Regulatory authorities may not accept for filing Alumis' planned NDA submission.
• Alumis' ability to obtain regulatory approval of and ultimately commercialize its clinical candidates is uncertain.
• The timing and results of preclinical and clinical trials may differ from expectations.
• Alumis' ability to fund development activities and achieve development goals is subject to risks and uncertainties.
• Alumis' ability to protect its intellectual property may be challenged.
• Actual results, levels of activity, safety, efficacy, performance, or events and circumstances could differ materially from those expressed or implied in forward-looking statements.
• Alumis may be adversely affected by economic, business, and/or competitive factors.
• The anticipated benefits and synergies of the recent merger with ACELYRIN, Inc. may not be fully realized or may take longer to realize than expected.
• Challenges inherent in developing, commercializing, manufacturing, launching, marketing, and selling potential existing and new products and product candidates.
• Uncertainties in contractual relationships, including collaborations, partnerships, licensing or other arrangements and the performance of third-party suppliers and manufacturers.
• Potential delays in initiating, enrolling, or completing preclinical studies and clinical trials.

Future Outlook

Alumis plans to submit a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis to the FDA in the second half of 2026. The company anticipates envudeucitinib has the potential to transform the treatment landscape for IL-23/IL-17 driven diseases and Type I interferon-driven diseases, including systemic lupus erythematosus, with LUMUS Phase 2b topline data expected in Q3 2026. They also expect to initiate a Phase 2 trial for A-005 in MS (Neuroinflammation) in H1 2026 and a Phase 1 trial for undisclosed IRF5/Additional Targets in H2 2026. The company projects a significant market opportunity for TYK2 molecules across various indications, with psoriasis and lupus markets alone expected to reach $40B and $11B respectively by 2032.

Management Comments

• "We believe envudeucitinib demonstrates the full promise of TYK2 inhibition. By maximally inhibiting TYK2, envudeucitinib blocks both IL-23 and IL-17 to deliver comprehensive disease control. In Phase 3, this translated into rapid onset of action, high rates of skin clearance, and meaningful symptom improvements that rank among the strongest reported for an oral therapy." Dr. Jørn Drappa, Chief Medical Officer of Alumis.
• "These pivotal data strengthen our conviction in envudeucitinib’s potential to transform the treatment landscape for IL-23/IL-17driven diseases as well as those driven by Type I interferon. These results reinforce our enthusiasm that envudeucitinib’s highly differentiated clinical profile positions it at the forefront of next-generation TYK2 inhibitors in psoriasis, with potential in systemic lupus erythematosus and beyond as a true pipeline-in-a-pill." Martin Babler, Chief Executive Officer of Alumis.

Industry Context

Plaque psoriasis affects over 8 million adults in the U.S., with many remaining inadequately controlled by current treatments. There is a significant unmet need for more effective, safe, and durable oral options. High-efficacy orals are expected to drive market growth in the projected $40B psoriasis market by 2030. TYK2 inhibition is a validated therapeutic approach for immune-mediated diseases, including those driven by IL-23/IL-17 and Type I interferon pathways. Envudeucitinib's profile, with leading skin clearance and a favorable safety profile, positions it as a strong contender in this market, potentially offering an oral alternative with efficacy comparable to biologics.

Comparison to Industry Standards

• Envudeucitinib's PASI 75, 90, and 100 response rates are similar to or greater than those reported for icotrokinra (from ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials).
• Envudeucitinib demonstrated superior skin clearance compared to apremilast (an existing oral therapy) in both ONWARD1 and ONWARD2 trials (p<0.0001).
• The efficacy results for envudeucitinib are presented as 'leading skin clearance among next-generation oral plaque psoriasis therapies,' suggesting it aims to surpass current oral options like Sotyktu (deucravacitinib) and potentially compete with biologics.
• A leading dermatologist, Dr. Andrew Blauvelt, noted that envudeucitinib offers an 'exciting possibility of a new oral drug for psoriasis that can deliver high levels of efficacy in a safe manner,' bridging the gap where biologics have long been superior to oral therapies for clearance.

Stakeholder Impact

• Shareholders: Highly positive clinical trial results and a clear path to NDA submission are likely to increase investor confidence and potentially the company's valuation.
• Patients: Envudeucitinib offers a promising new oral treatment option for moderate-to-severe plaque psoriasis with high efficacy and a favorable safety profile, potentially improving quality of life and disease management.
• Healthcare Providers: Provides a new, highly effective oral therapy that could bridge the gap between less effective oral treatments and injectable biologics, offering more options for patient care.
• Competitors: The strong results for envudeucitinib could increase competitive pressure on other companies developing or marketing psoriasis treatments, especially other oral TYK2 inhibitors.

Next Steps

• Present additional results from ONWARD1 and ONWARD2 at an upcoming medical meeting.
• Submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026 for envudeucitinib in plaque psoriasis.
• Announce topline data from the LUMUS Phase 2b trial of envudeucitinib in systemic lupus erythematosus (SLE) in the third quarter of 2026.
• Initiate Phase 2 trial for A-005 in MS (Neuroinflammation) in H1 2026.
• Initiate Phase 1 trial for Undisclosed IRF5/Additional Targets in H2 2026.

Key Dates

Recommendation

The filing presents exceptionally strong Phase 3 clinical trial results for envudeucitinib, demonstrating leading efficacy (high PASI 90/100 rates) and a favorable safety profile in moderate-to-severe plaque psoriasis. This positions envudeucitinib as a potential best-in-class oral therapy, capable of competing with biologics, and significantly de-risks its path to market with an NDA submission planned for H2 2026. The drug's 'pipeline-in-a-pill' potential for other immune-mediated diseases like SLE further enhances its long-term value proposition. These results are a major positive catalyst, indicating strong commercial prospects and significant upside for the company.

Keywords

Alumis, envudeucitinib, plaque psoriasis, Phase 3, TYK2 inhibitor, clinical trial, biopharmaceutical, NDA, FDA, systemic lupus erythematosus, LUMUS, ONWARD, dermatology, autoimmune disease, skin clearance